BioSpace News Archive

Simon Britton, a 30-year industry veteran with extensive global experience growing clinical development services and capabilities, will oversee the combined company’s operations.

Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW®) virtual annual meeting, taking place May 21-23

Kiromic is pleased to announce the identification of new targets for the treatment of solid tumors, identified through the application of its bioinformatics platform

The American Academy of Thermology, the nation’s premier medical thermology organization whose mission is to promulgate the use of infrared imaging into clinical medicine, announces the creation of three new platforms which will utilize a DICOM format to standardize acquisition.

ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Wall Street Unicorns in Process of Changing the Healthcare Landscape.”

TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR. InspireMD CEO Marvin Slosman said, “The trading of our shares on the Nasdaq Capital Market is a yet another very important step in t

Biofacturing leader Zymergen today announced the company will be participating in the upcoming UBS Global Healthcare Virtual Conference. Zymergen’s management is scheduled to present on Wednesday, May 26th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time.

CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FDA review with a target action date of June 1, 2021

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time.